These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 12102553)

  • 1. DNA modifications by antitumor platinum and ruthenium compounds: their recognition and repair.
    Brabec V
    Prog Nucleic Acid Res Mol Biol; 2002; 71():1-68. PubMed ID: 12102553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA binding mode of ruthenium complexes and relationship to tumor cell toxicity.
    Brabec V; Nováková O
    Drug Resist Updat; 2006 Jun; 9(3):111-22. PubMed ID: 16790363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modifications of DNA by platinum complexes. Relation to resistance of tumors to platinum antitumor drugs.
    Brabec V; Kasparkova J
    Drug Resist Updat; 2005 Jun; 8(3):131-46. PubMed ID: 15894512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular aspects of resistance to antitumor platinum drugs.
    Brabec V; Kasparkova J
    Drug Resist Updat; 2002; 5(3-4):147-61. PubMed ID: 12237082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA binding by antitumor trans-[PtCl2(NH3)(thiazole)]. Protein recognition and nucleotide excision repair of monofunctional adducts.
    Kasparkova J; Novakova O; Farrell N; Brabec V
    Biochemistry; 2003 Jan; 42(3):792-800. PubMed ID: 12534292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cisplatin and beyond: molecular mechanisms of action and drug resistance development in cancer chemotherapy.
    Makovec T
    Radiol Oncol; 2019 Mar; 53(2):148-158. PubMed ID: 30956230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New metal complexes as potential therapeutics.
    Zhang CX; Lippard SJ
    Curr Opin Chem Biol; 2003 Aug; 7(4):481-9. PubMed ID: 12941423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA interactions of monofunctional organometallic ruthenium(II) antitumor complexes in cell-free media.
    Novakova O; Chen H; Vrana O; Rodger A; Sadler PJ; Brabec V
    Biochemistry; 2003 Oct; 42(39):11544-54. PubMed ID: 14516206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA binding mode of the cis and trans geometries of new antitumor nonclassical platinum complexes containing piperidine, piperazine, or 4-picoline ligand in cell-free media. Relations to their activity in cancer cell lines.
    Kasparkova J; Marini V; Najajreh Y; Gibson D; Brabec V
    Biochemistry; 2003 May; 42(20):6321-32. PubMed ID: 12755637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New platinum, titanium, and ruthenium complexes with different patterns of DNA damage in rat ovarian tumor cells.
    Frühauf S; Zeller WJ
    Cancer Res; 1991 Jun; 51(11):2943-8. PubMed ID: 2032232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Energetics, conformation, and recognition of DNA duplexes containing a major adduct of an anticancer azolato-bridged dinuclear Pt(II) complex.
    Mlcouskova J; Malina J; Novohradsky V; Kasparkova J; Komeda S; Brabec V
    Biochim Biophys Acta; 2012 Oct; 1820(10):1502-11. PubMed ID: 22683702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA-protein cross-linking by trans-[PtCl(2)(E-iminoether)(2)]. A concept for activation of the trans geometry in platinum antitumor complexes.
    Novakova O; Kasparkova J; Malina J; Natile G; Brabec V
    Nucleic Acids Res; 2003 Nov; 31(22):6450-60. PubMed ID: 14602903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cellular pharmacology of cis and trans pairs of platinum complexes in cisplatin-sensitive and -resistant human ovarian carcinoma cells.
    O'Neill CF; Hunakova L; Kelland LR
    Chem Biol Interact; 1999 Nov; 123(1):11-29. PubMed ID: 10597899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA interactions of antitumor trans-[PtCl2(NH3)(quinoline)].
    Zákovská A; Nováková O; Balcarová Z; Bierbach U; Farrell N; Brabec V
    Eur J Biochem; 1998 Jun; 254(3):547-57. PubMed ID: 9688265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA interactions of new antitumor platinum complexes with trans geometry activated by a 2-metylbutylamine or sec-butylamine ligand.
    Prokop R; Kasparkova J; Novakova O; Marini V; Pizarro AM; Navarro-Ranninger C; Brabec V
    Biochem Pharmacol; 2004 Mar; 67(6):1097-109. PubMed ID: 15006546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential genotoxic effects of antitumor trans-[PtCl(2)(E-iminoether)(2)] and cisplatin in Escherichia coli.
    Janovská E; Nováková O; Natile G; Brabec V
    J Inorg Biochem; 2002 Jun; 90(3-4):155-8. PubMed ID: 12031808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biomolecular targets for platinum antitumor drugs.
    Bose RN
    Mini Rev Med Chem; 2002 Apr; 2(2):103-11. PubMed ID: 12370072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential recognition by the tumor suppressor protein p53 of DNA modified by the novel antitumor trinuclear platinum drug BBR3464 and cisplatin.
    Kasparkova J; Fojta M; Farrell N; Brabec V
    Nucleic Acids Res; 2004; 32(18):5546-52. PubMed ID: 15486204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Replacement of a thiourea with an amidine group in a monofunctional platinum-acridine antitumor agent. Effect on DNA interactions, DNA adduct recognition and repair.
    Kostrhunova H; Malina J; Pickard AJ; Stepankova J; Vojtiskova M; Kasparkova J; Muchova T; Rohlfing ML; Bierbach U; Brabec V
    Mol Pharm; 2011 Oct; 8(5):1941-54. PubMed ID: 21806015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Different features of the DNA binding mode of antitumor cis-amminedichlorido(cyclohexylamine)platinum(II) (JM118) and cisplatin in vitro.
    Kostrhunova H; Vrana O; Suchankova T; Gibson D; Kasparkova J; Brabec V
    Chem Res Toxicol; 2010 Nov; 23(11):1833-42. PubMed ID: 20939593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.